Rimegepant, sold under the brand name Nurtec ODT, has expanded its presence as a treatment and prevention option for adult migraines across multiple countries. As of December 15, 2023, regulatory approvals have been secured in the United States, United Arab Emirates, Israel, and Canada.
The oral tablet dissolves on or under the tongue and functions by blocking CGRP receptors, offering relief for migraines with or without aura. The medication’s regulatory path began in the United States in February 2020, when it received initial approval for acute migraine treatment. This milestone introduced a new therapeutic option for adults affected by the condition.
In June 2021, U.S. regulators expanded the approval to include prophylactic treatment of episodic migraine, broadening its potential applications. International approvals followed in March 2021, when the United Arab Emirates and Israel authorized rimegepant for medical use, marking its entry into new markets.
In the United Kingdom, the National Institute for Health and Care Excellence (NICE) has approved the drug for both acute treatment and prophylaxis of migraine in adults. Canada became the latest country to approve rimegepant in December 2023, providing Canadian adults with an additional management option. The medication’s mechanism of action—blocking CGRP receptors—represents a distinct approach to migraine therapy, potentially benefiting patients who have not responded to other treatments. This unique pathway distinguishes it from other available options.
Prescription data from 2023 indicates rimegepant has become a commonly prescribed medication in the United States, with more than 2 million prescriptions filled that year. It ranks as the 206th most prescribed medication in the country, suggesting healthcare providers are incorporating it into patient care for a substantial number of individuals.
Ongoing monitoring of rimegepant’s use and effectiveness across different patient groups will be important as its global reach expands. With growing adoption and regulatory approvals, the medication is expected to remain a focus within the healthcare community. Future research may provide further insights into its benefits, limitations, and potential to improve outcomes for migraine sufferers.
The Canadian approval represents a significant step in the medication’s international availability, and continued developments in migraine treatment and prevention are anticipated in the coming years.
